Platelet volume indices are associated with systolic and diastolic cardiac dysfunction, and left ventricular hypertrophy

Shu-ichi Fujita†, Yoshihiro Takeda†, Shun Kizawa†, Takahide Ito†, Kazushi Sakane†, Toshiyuki Ikemoto‡, Yoshikatsu Okada‡, Koichi Sohmiya†, Masaaki Hoshiga† and Nobukazu Ishizaka∗

Abstract

Background: Mean platelet volume (MPV) and platelet distribution width (PDW) are indices that reflect platelet activity. We investigated the association between these platelet indices and left ventricular hypertrophy and cardiac function.

Methods: We analyzed the data of 1241 patients who were admitted to the Cardiology Department.

Results: Both MPV and PDW were selected as independent factors associated with left ventricular systolic and diastolic dysfunction, and left ventricular hypertrophy. The highest tertile of MPV and PDW was associated with left ventricular systolic dysfunction (left ventricular ejection fraction of <50 %) with an odds ratio of 1.53 and 2.03, respectively, when the respective lowest tertile was used as reference. The highest PDW tertile was associated with left ventricular hypertrophy with an odds ratio of 1.56 (95 % CI, 1.13–2.15) and with dysfunction with an odds ratio of 3.34 (95 % CI, 1.54–7.25).

Conclusions: Indices of platelet activation (MPV and/or PDW) were independently associated positively with left ventricular hypertrophy and left ventricular systolic and diastolic dysfunction. Whether these platelet indices represent useful markers for identifying individuals at higher risk for thromboembolic disease and organ damage among cardiac patients awaits further investigation.

Keywords: Platelet function, Left ventricular hypertrophy, Cardiac function, Antithrombotic drugs

Background

Activation of platelets and their subsequent aggregation play a key role in thrombus formation at the site of vascular injury and atherothrombotic events [1, 2]. Assessment of platelet activity and proper medical control are therefore mandatory for high-risk patients [3]; however, platelet aggregation after applying inducers, such as adenosine diphosphate (ADP) or 5-hydroxytryptamine, and collagen, is, in general, not measured in routine laboratory testing.

In comparison to smaller ones, larger platelets have higher thrombotic potential [4] that may be partially attributed to a higher thromboxane A2 level [5] and increased expression of glycoprotein Ib and IIb/IIIa receptors [6]. Mean platelet volume (MPV), which is the most accurate measure of platelet size, is a simple, easy to quantify, inexpensive, and widely available marker of platelet activation [7]. MPV has received substantial attention in the past few years for the purpose of risk prediction and risk stratification of various disorders, especially ischemic heart disease, in the cardiology field [4, 8–11]. Platelet distribution width (PDW), which is in general positively correlated with MPV, directly measures the variability in platelet size, and also represents a parameter of platelet activity [12]. Several previous studies have assessed PDW values among patients with acute coronary syndrome or coronary artery disease [13–15]. MPV may be increased in other cardiovascular conditions such as pulmonary arterial hypertension [16], hypertrophic...
cardiomyopathy [17], and decompensated heart failure [18, 19], which may explain the increase in thromboembolic events in these conditions [20]. Until now, only a few studies with small sample sizes have examined the relationship between MPV and left ventricular systolic and diastolic dysfunction, and left ventricular hypertrophy [21–23]. To this end, in the current study, we analyzed the relationship between platelet indices (MPV, PDW) and left ventricular systolic and diastolic cardiac dysfunction and hypertrophy among patients admitted to the Cardiology Department.

**Methods**

**Study population**

The current retrospective study was approved by the Ethics Committee of Osaka Medical College. Between January 2012 and March 2014, 1241 patients who were admitted to the Cardiology Department and had provided written informed consent and for whom sufficient information regarding the data analysis for the current study including echocardiographic data was available were enrolled in the current study. Left ventricular diastolic dysfunction (LVDD) was assessed among the patients with both sinus rhythm and left ventricular ejection fraction (LVEF) of ≥50 %. Of 1241 overall study population, 821 patients were found to have both sinus rhythm and LVEF of ≥50 %. Among these patients, however, echocardiographic data that was necessary for the determination of the presence or absence of diastolic dysfunction was not available in 237 patients due to the poor echocardiographic imaging. Therefore, data from subgroup of 584 patients were used for the analysis of the relationship between platelet indices and LVDD.

**Laboratory analysis**

C-reactive protein (CRP) and B-type natriuretic peptide (BNP) were measured by routine laboratory methods. The eGFR was calculated by the following Modification of Diet in Renal Disease equation for Japanese subjects: eGFR mL/min/1.73 m² = 194 × (serum creatinine) −1.094 × (age) −0.287 (×0.739, when female) [24]. eGFR of less than 60 mL/min/1.73 m² was defined as chronic kidney disease in the current study. MPV and PDW were analyzed within 2 h of venipuncture by automatic blood counter (ADVIA 2120i Hematology System; Siemens, Inc.) used for whole blood analysis, with an intra-assay coefficient of variation <1.4 % and 5.9 %, respectively.

**Echocardiography**

Echocardiographic examinations were performed as described previously [25]. Briefly, left ventricular (LV) volumes were calculated using the modified Simpson method in the apical 4-chamber view. For calculation of the LV mass (LVM), we used the formula proposed by Devereux et al. [26] with modification: 0.8 × 1.04 × [(LVDD + IVST + PWT)³ - LVDD³] + 0.6. LVM index (LVMI) was calculated as the ratio of LVM to the body surface area. Left ventricular hypertrophy (LVH) was defined to be present when the LVMI was greater than 118 g/m² (men) or 108 g/m² (women) [27]. The LVEF was calculated by modified Simpson's method using the apical 4-chamber view and left ventricular systolic dysfunction (LVSD) was defined to be present when LVEF was less than 50 %.

LVDD was assessed as previously described [28]. Briefly, the deceleration time of the E wave (DcT) and peak velocities of early filling (E) and atrial filling (A) were measured, and the early peak diastolic mitral annulus velocity (e'), which was the mean of that obtained at the septal and lateral mitral annulus, was measured using pulsed wave tissue Doppler. LVDD was diagnosed when any the following criteria were met; (1) E/e' ≥ 15, (2) 15 > E/e' ≥ 8 and BNP ≥ 200, (3) 15 > E/e' ≥ 8, E/A < 0.5, and DcT ≥ 280 msec, (4) 15 > E/e' ≥ 8, E/A < 0.5 and presence of LVH.

**Statistical analysis**

Baseline characteristics were assessed with standard descriptive statistics. Data were expressed as either mean ± standard deviation or median and interquartile range. A Pearson’s correlation test was used to assess the correlation between two variables. For multivariate analysis, multivariate linear regression and multivariate logistic regression analyses were used. Data analysis was performed by SPSS statistics version 22.0 (IBM, Armonk, NY). A value of P < 0.05 was taken to be statistically significant.

**Results**

**Patient characteristics**

Among the 1241 patients enrolled, 910 were male (73 %) and 1008 (81 %) had sinus rhythm (Table 1). Only 53 (4 %) patients were undergoing chronic hemodialysis. Platelet count was significantly negatively associated with MPV and PDW, and MPV showed a significant positive correlation with PDW (Fig. 1). Echocardiography showed that 263 (21 %) patients had LVSD and 448 (36 %) had LVH.

**Relationship between antithrombotic drug usage and platelet indices**

About one third of the study patients were taking anti-coagulant medication and more than half were taking aspirin and/or other antiplatelet drugs. Some platelet indices differed between the anti-thrombotic drug users and the non-users (Fig. 2); patients taking aspirin or clopidogrel had significantly lower MPV as compared with non-users (Fig. 2b). In addition, patients taking warfarin
had a lower platelet count and higher MPV as compared with non-users (Fig. 2d, e), although these values did not significantly differ according to the use and non-use of non-warfarin novel oral anticoagulants (NOAC).

It was found that the MPV value in patients with atrial fibrillation (8.59 ± 0.91 fl) was significantly higher than that in patients with sinus rhythm (8.25 ± 0.87 fl, \( P < 0.001 \)). When the comparison was limited to patients with sinus rhythm, the MPV values in patients with warfarin usage and that in patients without warfarin usage did not differ significantly (8.24 ± 0.87 fl versus 8.34 ± 0.87 fl, respectively, \( P = 0.202 \)). In addition, MPV did not differ significantly between warfarin users and non-users among patients with sinus rhythm who were taking at least one anti-platelet medication (8.33 ± 0.86 fl \([n = 92]\) versus 8.21 ± 0.87 fl \([n = 669]\), \( P = 0.203 \)) or among patients with sinus rhythm who were not taking any anti-platelet medication (8.35 ± 0.91 fl \([n = 53]\) versus 8.35 ± 0.87 fl \([n = 194]\), \( P = 0.959 \)).

### Relationship between platelet indices and left ventricular systolic function and hypertrophy

When the data were assessed in tertiles, the prevalence of LVSD seemed to increase according to the MPV (Fig. 3a) or PDW (Fig. 3b) tertile, but not the platelet count tertile. This tendency seemed to be less apparent for the prevalence of LVH (Fig. 3c, d). In univariate linear regression analysis, platelet count, MPV, and PDW were each significantly associated with both LVEF and LVMI (Table 2). When stepwise multivariate analysis was performed by entering all of the variables that used in univariate analysis, MPV and PDW, but not platelet count, were found to have a significant association with LVEF and LVMI.

### Multivariate logistic regression analysis of the relationship with left ventricular systolic dysfunction and hypertrophy

Next, we performed multivariate logistic regression analyses using LVSD or LVH as a dependent variable (Tables 3 and 4). In this analysis, use of antiplatelet drugs and use of warfarin were entered as independent variables. Warfarin use was found to be, respectively, significantly and borderline significantly positively associated with LVSD and LVH in model 1, where platelet indices were entered on a per 1 standard deviation (SD) basis, PDW was, respectively, significantly and borderline significantly associated with LVSD and LVH. In this model, the association between MPV and LVH was not significant; however, in an analysis adjusted for sex, age, anti-platelet drug use, and warfarin use, MPV was significantly associated with LVSD with an odds ratio of 1.26 (95 % CI 1.12–1.42, per 1 SD, \( P < 0.001 \)).

In model 2, where platelet indices were entered as tertile basis, the highest tertile of MPV and PDW was associated

### Table 1 Clinical characteristics of the study patients

| Variables                        | Women (n = 331) | Men (n = 910) |
|----------------------------------|----------------|--------------|
| Age, years                       | 71.1 ± 10.9    | 68.3 ± 10.8  |
| Body mass index, kg/m\(^2\)      | 22.9 ± 4.1     | 23.7 ± 3.5   |
| Chronic hemodialysis, n (%)      | 8 (2.4)        | 45 (4.9)     |
| Ever smoker                      | 55 (16.6)      | 721 (79.2)   |
| Cardiovascular disease           |                |              |
| Ischemic heart disease, n (%)    | 173 (52.3)     | 681 (74.8)   |
| Arrhythmic disease, n (%)        | 35 (10.6)      | 70 (7.7)     |
| Cardiomyopathy, n (%)            | 113 (34.1)     | 217 (23.8)   |
| Peripheral artery disease, n (%) | 15 (4.5)       | 82 (9.0)     |
| Valvular heart disease, n (%)    | 34 (10.3)      | 71 (7.8)     |
| Medication                       |                |              |
| ACE inhibitors/ARB, n (%)        | 150 (45.3)     | 524 (57.6)   |
| Beta blockers, n (%)             | 123 (37.2)     | 372 (40.9)   |
| Calcium channel blockers, n (%)  | 162 (48.9)     | 389 (42.7)   |
| Loop diuretics, n (%)            | 102 (30.8)     | 202 (22.2)   |
| Thiazide diuretics, n (%)        | 25 (7.6)       | 38 (4.2)     |
| Aldosterone antagonist, n (%)    | 35 (10.6)      | 79 (8.7)     |
| Aspirin, n (%)                   | 166 (50.2)     | 658 (72.3)   |
| Clopidogrel, n (%)               | 88 (26.6)      | 393 (43.2)   |
| Any antiplatelet drug, n (%)     | 176 (53.2)     | 689 (75.7)   |
| Warfarin, n (%)                  | 78 (23.6)      | 202 (22.2)   |
| NOAC, n (%)                      | 40 (12.1)      | 79 (8.7)     |
| Any anticoagulants, n (%)        | 118 (35.6)     | 281 (30.9)   |
| Laboratory data                  |                |              |
| White blood cell count, x10\(^3\)/μL | 5.67 (4.60–6.86) | 6.07 (4.98–7.27) |
| Hemoglobin, g/dL                 | 12.4 (11.2–13.5) | 13.6 (12.3–14.8) |
| Platelet count, x10\(^3\)/μL     | 212 (172–259)  | 201 (171–239) |
| Mean platelet volume, fl         | 8.1 (7.7–8.7)  | 8.2 (7.7–8.8) |
| Platelet distribution width, %   | 52.0 (47.3–56.2)| 53.1 (48.3–58.0) |
| Serum creatinine, mg/dL          | 0.72 (0.62–0.93)| 0.92 (0.80–1.13) |
| eGFR, ml/min/1.73 m\(^2\)       | 60.4 (45.9–71.8)| 47 (37.3–55.9) |
| Echocardiographic data           |                |              |
| LV diastolic dimension, cm       | 4.6 (4.2–5.1)  | 4.9 (4.6–5.5) |
| LV systolic dimension, cm        | 2.9 (2.5–3.5)  | 3.3 (2.9–3.9) |
| LV ejection fraction, %          | 61 (54–68)     | 59 (51.0–65) |
| LV mass index, g/m\(^2\)         | 99 (83–123)    | 106 (89.9–128) |

ACE, angiotensin converting enzyme; ARB, angiotensin receptor blockers; NOAC, non-warfarin novel oral anticoagulants. For the data of serum creatinine and eGFR, patients on chronic hemodialysis (n = 53) were excluded from the analysis.
with LVSD with an odds ratio of 1.53 and 2.03, respectively, compared with the respective lowest tertile (Table 3).

Relationship between platelet indices and left ventricular diastolic dysfunction
Next, the relationship between platelet indices and LVDD was investigated. Among 584 patients for whom presence or absence of diastolic dysfunction was assessed, 71 patients (12.2 %) were found to have LVDD. In model 1 where platelet indices were entered on a per 1 SD basis, platelet count and PDW, respectively, were found to be significantly negatively and positively associated with LVDD (Table 5). In this model, the association between MPV and LVDD was not significant; however, in an analysis adjusted for sex, age, anti-platelet drug use, and warfarin use, MPV was significantly associated with LVDD with an odds ratio of 1.34 (95 % CI, 1.02–1.76, per 1 SD, \(P = 0.036\)). In model 2, where platelet indices were entered on a tertile basis, the highest tertile of PDW was associated with LVDD with an odds ratio of 3.34 compared with the lowest tertile (Table 5).
Discussion

In the current study, we analyzed platelet indices and cardiac hypertrophy and left ventricular systolic and diastolic function among cardiac patients. In a univariate analysis, platelet count, MPV, and PDW were each correlated with LVEF and LVMI; however, stepwise multivariate regression analysis showed that MPV and PDW, but not platelet count, were independently associated with LVEF and LVMI. By multivariate logistic regression analysis, the highest tertile of MPV and PDW was associated with left ventricular systolic dysfunction (LVEF < 50 %) with an odds ratio of 1.53 and 2.03, respectively, as compared with the respective lowest tertile (Table 3). Platelet count and PDW were found to be independently associated with LVH and with LVSD. MPV was associated with both LVH and LVSD after adjusting for sex, age, anti-platelet drug usage, and warfarin usage; however, after further adjustment for covariates including platelet count and PDW, these associations lost statistical significance, which was explained, at least in part, by the inter-relationship among platelet count, MPV, and PDW (Fig. 1).

Some studies previously showed the relationship between MPV and cardiac function/hypertrophy [19, 21–23]. In the current study, more than 1200 patients were studied for the association between platelet indices and cardiac systolic dysfunction/hypertrophy, and more than 580 patients were studied for the association between platelet indices and cardiac diastolic dysfunction. We also carefully assessed whether the antithrombotic medication use affected the observed relation between platelet indices and cardiac parameters. In addition, there have been no studies examining the relationship between platelet indices and heart failure in Japanese population.

Among the current study patients, approximately one-third and more than half, respectively, were taking anticoagulant medication and antiplatelet drugs. MPV values were lower among patients who were taking either aspirin or clopidogrel as compared with those who were not (Fig. 2b). Some studies have demonstrated that aspirin [29, 30] or dual antiplatelet therapy [31] may not significantly affect MPV, and one study showed a paradoxical increase in MPV after antiplatelet therapy was started [32], which might be related to a lack of patients response to clopidogrel [33]. The reason why antiplatelet drugs reduced MPV in the current study is unclear. Whether lower MPV values predict cardiovascular risk or restenosis after percutaneous coronary intervention among patients taking antiplatelet drugs [34] awaits future investigation.

Warfarin, but not NOAC, usage was found to be associated with the increased MPV value (Fig. 2e). Arik previously reported that MPV was not significantly altered by warfarin when it effectively prolonged international normalized ratio
among patients with non-valvular atrial fibrillation [35]. It has been reported that MPV is higher in patients with atrial fibrillation than in those with sinus rhythm [36, 37]. Because the association between warfarin use and MPV lost statistical significance, irrespective of antiplatelet drug use, when limited to the population with sinus rhythm in the current study, the association observed between warfarin and MPV may be attributed to the presence of atrial fibrillation. We also showed that NOAC did not affect platelet factors. In several previous studies, a relationship between MPV and left ventricular systolic function and hypertrophy has been reported: for example, MPV has been found to have a positive [22, 38] or no [39–41] association with LVH and a negative association with LVEF [21, 42]. On the other hand, most studies did not take PDW or antithrombotic drug use into account.

LVDD may increase the risk of stroke [43, 44]. Although previous studies demonstrated the platelet activation in patients with heart failure [20, 45], a relationship between platelet factors in patients with LVSD seems not to have been specifically investigated. Our study found that platelet count and PDW, respectively, were negatively and positively associated with LVDD among the subgroup of patients who had sinus rhythm and preserved left ventricular systolic function (Table 5). MPV was not independently associated with LVDD after full adjustment including PDW, which might be related to the fact that PDW is a more specific marker of platelet activation [46].

Table 3 Multivariate logistic regression analysis of factors associated with LVSD

| Independent variables               | Odds ratio (95 % CI) | P value | Odds ratio (95 % CI) | P value |
|-------------------------------------|----------------------|---------|----------------------|---------|
|                                    | Univariate           |         | Multivariate (stepwise) |         |
|                                    | Std β    | P value | Std β    | P value |
| Sex (male = 1)                      | 1.08 (0.74–1.58)     | 0.700   | 1.07 (0.73–1.56)     | 0.743   |
| Age                                 | 0.83 (0.71–0.97)      | 0.018   | 0.83 (0.71–0.97)      | 0.017   |
| Systolic blood pressure, per 1SD    | 0.87 (0.75–1.01)      | 0.059   | 0.87 (0.75–1.01)      | 0.062   |
| Chronic kidney disease              | 1.56 (1.03–2.36)      | 0.036   | 1.60 (1.05–2.43)      | 0.027   |
| Any antiplatelet drugs              | 1.00 (0.72–1.38)      | 0.997   | 0.98 (0.71–1.35)      | 0.888   |
| Warfarin                            | 2.18 (1.58–2.99)      | <0.001  | 2.18 (1.58–2.99)      | <0.001  |
| White blood cell count, per 1SD     | 1.19 (1.03–1.37)      | 0.016   | 1.18 (1.03–1.36)      | 0.017   |
| Hemoglobin, per 1SD                 | 0.78 (0.67–0.90)      | 0.001   | 0.79 (0.68–0.91)      | 0.001   |
| Platelet count, per 1SD             | 0.90 (0.76–1.06)      | 0.206   |                     |         |
| MPV, per 1SD                        | 1.15 (0.98–1.35)      | 0.096   |                     |         |
| PDW, per 1SD                        | 1.25 (1.06–1.46)      | 0.007   |                     |         |
| Middle platelet tertile             |                      |         | 0.80 (0.56–1.14)      | 0.218   |
| Highest platelet tertile            |                      |         | 0.83 (0.56–1.23)      | 0.346   |
| Middle MPV tertile                  |                      |         | 1.18 (0.80–1.73)      | 0.412   |
| Highest MPV tertile                 |                      |         | 1.53 (1.04–2.27)      | 0.033   |
| Middle PDW tertile                  |                      |         | 1.80 (1.22–2.64)      | 0.003   |
| Highest PDW tertile                 |                      |         | 2.03 (1.37–3.02)      | <0.001  |

In model 2, platelet indices used in model 1 were used replaced by tertile of these variables, and the odds ratio of the middle and the highest tertile was calculated using the corresponding lowest tertile
### Table 4 Multivariate logistic regression analysis of factors associated with LVH

| Independent variables                  | Odds ratio (95% CI) model 1 | P value | Odds ratio (95% CI) model 2 | P value |
|----------------------------------------|-----------------------------|---------|-----------------------------|---------|
| Sex (male = 1)                         | 0.87 (0.63–1.19)            | 0.386   | 0.86 (0.62–1.18)            | 0.356   |
| Age, per 1SD                           | 0.93 (0.81–1.06)            | 0.264   | 0.93 (0.81–1.06)            | 0.276   |
| Systolic blood pressure, per 1SD       | 1.22 (1.08–1.37)            | 0.002   | 1.22 (1.08–1.38)            | 0.001   |
| Chronic kidney disease                 | 1.69 (1.20–2.36)            | 0.002   | 1.75 (1.25–2.46)            | 0.001   |
| Any antiplatelet drugs                 | 0.80 (0.61–1.05)            | 0.103   | 0.79 (0.60–1.04)            | 0.092   |
| Warfarin                               | 1.30 (0.97–1.74)            | 0.075   | 1.30 (0.97–1.74)            | 0.074   |
| White blood cell count, per 1SD        | 1.12 (0.99–1.27)            | 0.074   | 1.11 (0.98–1.26)            | 0.101   |
| Hemoglobin, per 1SD                    | 0.72 (0.63–0.82)            | <0.001  | 0.72 (0.63–0.82)            | <0.001  |
| Platelet count, per 1SD                | 0.93 (0.81–1.07)            | 0.303   |                            |         |
| MPV, per 1SD                           | 1.10 (0.96–1.27)            | 0.171   |                            |         |
| PDW, per 1SD                           | 1.12 (0.98–1.29)            | 0.095   |                            |         |
| Middle platelet tertile                |                            |         | 0.80 (0.59–1.09)            | 0.160   |
| Highest platelet tertile               |                            |         | 0.94 (0.67–1.31)            | 0.697   |
| Middle MPV tertile                     |                            |         | 1.15 (0.84–1.56)            | 0.388   |
| Highest MPV tertile                    |                            |         | 1.28 (0.92–1.77)            | 0.139   |
| Middle PDW tertile                     |                            |         | 1.39 (1.02–1.88)            | 0.035   |
| Highest PDW tertile                    |                            |         | 1.56 (1.13–2.15)            | 0.007   |

In model 2, platelet indices used in model 1 were used replaced by tertile of these variables, and the odds ratio of the middle and the highest tertile was calculated using the corresponding lowest tertile.

### Table 5 Multivariate logistic regression analysis of factors associated with LVDD

| Independent variables                  | Odds ratio (95% CI) model 1 | P value | Odds ratio (95% CI) model 2 | P value |
|----------------------------------------|-----------------------------|---------|-----------------------------|---------|
| Sex (male = 1)                         | 0.42 (0.21–0.84)            | 0.014   | 0.37 (0.18–0.75)            | 0.006   |
| Age, per 1SD                           | 1.34 (0.95–1.89)            | 0.095   | 1.30 (0.92–1.83)            | 0.139   |
| Systolic blood pressure, per 1SD       | 1.17 (0.89–1.56)            | 0.263   | 1.20 (0.91–1.60)            | 0.200   |
| Chronic kidney disease                 | 2.43 (1.12–5.30)            | 0.025   | 2.78 (1.24–6.24)            | 0.013   |
| Any antiplatelet drugs                 | 0.59 (0.30–1.15)            | 0.123   | 0.65 (0.33–1.29)            | 0.220   |
| Warfarin                               | 1.11 (0.47–2.61)            | 0.810   | 1.11 (0.47–2.62)            | 0.811   |
| White blood cell count, per 1SD        | 1.54 (1.14–2.07)            | 0.005   | 1.52 (1.13–2.03)            | 0.005   |
| Hemoglobin, per 1SD                    | 0.50 (0.37–0.66)            | <0.001  | 0.51 (0.38–0.67)            | <0.001  |
| Platelet count, per 1SD                | 0.62 (0.46–0.86)            | 0.003   |                            |         |
| MPV, per 1SD                           | 0.92 (0.66–1.29)            | 0.641   |                            |         |
| PDW, per 1SD                           | 1.41 (1.03–1.92)            | 0.031   |                            |         |
| Middle platelet tertile                |                            |         | 0.42 (0.21–0.82)            | 0.011   |
| Highest platelet tertile               |                            |         | 0.32 (0.15–0.67)            | 0.003   |
| Middle MPV tertile                     |                            |         | 1.00 (0.49–2.04)            | 0.991   |
| Highest MPV tertile                    |                            |         | 0.88 (0.42–1.86)            | 0.738   |
| Middle PDW tertile                     |                            |         | 1.91 (0.90–4.05)            | 0.092   |
| Highest PDW tertile                    |                            |         | 3.34 (1.54–7.25)            | 0.002   |

In model 2, platelet indices used in model 1 were used replaced by tertile of these variables, and the odds ratio of the middle and the highest tertile was calculated using the corresponding lowest tertile.
Notably, however, MPV was associated with LVDD with an odds ratio of 1.34 (95% CI 1.02–1.76) in a model adjusted for sex, age, and use of anti-platelet drugs and warfarin. Whether PDV and MPV are useful parameters for discriminating patients with LVDD and those at higher risk for future thromboembolic risk and target organ damage [38] needs to be investigated in future studies.

There are several limitations to the current study. First, we did not directly assess the platelet aggregation induced by ADP or other agonists. Second, because of the cross-sectional nature of the study, we did not have data regarding future thromboembolic risk among patients with high MPV or PDV value. Third, whether MPV and PDW are useful predictors of future thromboembolic risk and targets for pharmacological intervention should be investigated in future prospective studies. Fourth, as we did not directly measure the platelet function, some conclusions may be based on the speculative discussion. On the other hand, as MPV and PDW are easily acquired parameters, we may verify whether measurement of these parameters is of use for prediction of cardiovascular events in future studies.

Conclusion
In conclusion, we herein demonstrated that usage of antiplatelet drug and warfarin was related to MPV, and that the platelet indices MPV and PDW, but not platelet count, were independently associated with left ventricular systolic function and mass index. Among patients with preserved systolic function and sinus rhythm, the highest PDV tertile was associated with LVDD with an odds ratio of 1.56 (95% CI, 1.13–2.15) when compared with the lowest PDW tertile after multivariate adjustment. Whether these platelet indices represent useful markers for discriminating those at higher risk for thromboembolic disease and organ damage among cardiac patients awaits further investigation.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
SF performed the statistical analysis; YT gathered the data and create database. SK gathered the data; TI (Takahide Ito) supervised the echocardiography. KS (Kazushi Sakane) made substantial contributions to gathering the data. TI (Takahide Ito) measured the platelet indices. YO measured the platelet volume in hypertrophic cardiomyopathy. Angiology. 2011;65(5):420. TI (Takahide Ito) supervised the echocardiography. KS (Kazushi Sakane) made substantial contributions to gathering the data. TI (Takahide Ito) measured the platelet indices. YO measured the platelet volume in hypertrophic cardiomyopathy. Angiology. 2011;65(5):420. TI (Takahide Ito) supervised the echocardiography. KS (Kazushi Sakane) made substantial contributions to gathering the data. TI (Takahide Ito) measured the platelet indices. YO measured the platelet volume in hypertrophic cardiomyopathy. Angiology. 2011;65(5):420. TI (Takahide Ito) supervised the echocardiography. KS (Kazushi Sakane) made substantial contributions to gathering the data. TI (Takahide Ito) measured the platelet indices. YO measured the platelet volume in hypertrophic cardiomyopathy. Angiology. 2011;65(5):420.

Acknowledgements
We are highly appreciative of Chieko Ohta, Yumiko Ohgami, and Megumi Hashimoto for their excellent technical assistance.

Author details
1Department of Cardiology, Osaka Medical College, Takatsuki-shi Daigaku-machi 2-7, Osaka 569-8686, Japan. 2Department of Central Clinical Laboratory, Osaka Medical College, Osaka, Japan.

Received: 10 February 2015 Accepted: 1 June 2015 Published online: 16 June 2015

References
1. Marczewski MM, Postula M, Kosior D. Novel antiplatelet agents in the prevention of cardiovascular complications-focus on ticagrelor. Vasc Health Risk Manag. 2010;6:419–29.
2. Ueno M, Kodali M, Tello-Montoliu A, Angiolillo DJ. Role of platelets and antiplatelet therapy in cardiovascular disease. J Atheroscler Thromb. 2011;18(6):431–42.
3. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation. 2004;110(19):e489–93.
4. Slavka G, Perkmann T, Haslacher H, Greisenegger S, Marsik C, Wagner OF; et al. Mean platelet volume may represent a predictive parameter for overall vascular mortality and ischemic heart disease. Antithrombot Thromb Vasc Biol. 2011;31(5):1215–8.
5. Jakubowski JA, Thompson CB, Vailancourt R, Valeri CR, Deykyn D. Arachidonic acid metabolism by platelets of differing size. Br J Haematol. 1985;53(3):503–11.
6. Giles H, Smith RE, Martin JF. Platelet glycoprotein IIb-IIIa and size are increased in acute myocardial infarction. Eur J Clin Invest. 1994;24(1):69–72.
7. Park Y, Schoene N, Harris W. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets. 2002;13(5–6):301–6.
8. Burr ML, Holiday RM, Feihly AW, Whitehead PJ. Haematological prognostic indices after myocardial infarction: evidence from the diet and reincarnation trial (DART). Eur Heart J. 1992;13(2):166–70.
9. Endler G, Klimesch A, Sunder-Plassmann H, Schillingler M, Exner M, Mannhalter C; et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol. 2002;117(2):399–404.
10. Taglieri N, Saia F, Rapezi C, Marrozzini C, Bacchi Reggiani ML, Palmerrini T; et al. Prognostic significance of mean platelet volume on admission in an unselected cohort of patients with non ST-segment elevation acute coronary syndrome. Thromb Haemost. 2011;106(1):132–40.
11. Sansanayudh N, Anothaisintawee T, Muntham D, McEvoy M, Attia J, Ahrar津Thakkaristan. Mean platelet volume and coronary artery disease: a systematic review and meta-analysis. Int J Cardiol. 2014;175(3):433–40.
12. Jurcut R, Arsenescu I, Puschel G, Idoie I, Apetrei E; et al. Is interleukin-18 correlated with endothelial dysfunction and platelet activation in patients with unstable angina? Rom J Intern Med. 2005;43(3–4):199–209.
13. Khandekar MM, Khurana AS, Deshmukh SD, Kakrani AL, Kaldare AD, Inamdar AK. Platelet volume indices in patients with coronary artery disease and acute myocardial infarction: an Indian scenario. J Clin Pathol. 2006;59(2):146–9.
14. Khode V, Sundhir J, Kanbur D, Ruiker K, Nalluvaru S. Mean platelet volume and other platelet volume indices and acute myocardial infarction and other platelet volume indices in patients with stable coronary artery disease: a case control study. J Cardiovasc Di Res. 2012;3(4):222–5.
15. Assiri AS, Jamil AM, Mahfouz AA, Mahmoud ZS, Ghallab M. Diagnostic importance of platelet parameters in patients with acute coronary syndrome admitted to a tertiary care hospital in southwest region. Saudi Arabia J Saudi Heart Assoc. 2012;24(1):17–21.
16. Varol E, Uysal BA, Ozaydin M. Platelet indices in patients with pulmonary arterial hypertension. Clin Appl Thromb Hemost. 2011;17(6):E171–4.
17. Icli A, Aksoy F, Dogan A, Arslan A, Akguz S, Yuvel H; et al. Increased mean platelet volume in hypertrophic cardiomyopathy. Angiology. 2014;65(5):420–4.
18. Malinin AI, O’Conor CM, Dhahathawewa AI, Sane DC, Serebruany V. Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel? Am Heart J. 2003;145(3):397–403.
19. Kandis H, Ozhan H, Oktu S, Erden I, Caglar O, Basar C; et al. The prognostic value of mean platelet volume in decompensated heart failure. Emerg Med J. 2011;28(7):575–8.
20. Chung I, Choudhury A, Lip GY. Platelet activation in acute, decompensated congestive heart failure. Thromb Res. 2007;120(5):709–13.
21. Acikgoz N, Ermis N, Yagmur J, Cansel M, Atas H, Pekdemir H; et al. The prognostic evaluation of mean platelet volume levels in patients with idiopathic and ischemic heart disease. Arterioscler Thromb Vasc Biol. 2011;31(5):1215–8.
22. Scuteri A, Cacciafesta M, de Propris AM, di Bernardo MG, Recchi D, Celli V; et al. Mean platelet volume may represent a predictive parameter for overall vascular mortality and ischemic heart disease. Antithrombot Thromb Vasc Biol. 2011;31(5):1215–8.
23. Ueno M, Kodali M, Tello-Montoliu A, Angiolillo DJ. Role of platelets and antiplatelet therapy in cardiovascular disease. J Atheroscler Thromb. 2011;18(6):431–42.
24. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation. 2004;110(19):e489–93.
25. Slavka G, Perkmann T, Haslacher H, Greisenegger S, Marsik C, Wagner OF; et al. Mean platelet volume may represent a predictive parameter for overall vascular mortality and ischemic heart disease. Antithrombot Thromb Vasc Biol. 2011;31(5):1215–8.
26. Jakubowski JA, Thompson CB, Vailancourt R, Valeri CR, Deykyn D. Arachidonic acid metabolism by platelets of differing size. Br J Haematol. 1985;53(3):503–11.
27. Giles H, Smith RE, Martin JF. Platelet glycoprotein IIb-IIIa and size are increased in acute myocardial infarction. Eur J Clin Invest. 1994;24(1):69–72.
28. Park Y, Schoene N, Harris W. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets. 2002;13(5–6):301–6.
24. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–92.

25. Shibata K, Fujita S, Morita H, Okamoto Y, Soshima K, Hoshiga M, et al. Association between circulating fibroblast growth factor 23, alpha-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients. PLoS One. 2013;8(9), e73184.

26. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method Circulation. 1977;55(4):613–8.

27. Hashimoto J, Watabe D, Hatanaka R, Hanasawa T, Metoki H, Asayama K, et al. Enhanced radial late systolic pressure augmentation in hypertensive patients with left ventricular hypertrophy. Am J Hypertens. 2006;19(1):27–32.

28. Okamoto Y, Fujita S, Morita H, Kizawa S, Ito T, Sakane K, et al. Association between circulating FGF23, alpha-Klotho, and left ventricular diastolic dysfunction among patients with preserved ejection fraction. Heart Vessels. 2014. doi:10.1007/s00380-014-0581-9.

29. Colkesen Y, Coskun I, Muderrisoglu H. The effect of aspirin on mean platelet volume in patients with paroxysmal atrial fibrillation. Platelets. 2013;24(4):263–6.

30. Shah B, Valdes V, Nardi MA, Hu L, Schrem E, Berger JS. Mean platelet volume reproducibility and association with platelet activity and anti-platelet therapy. Platelets. 2014;25(3):188–92.

31. Higaki T, Kurisu S, Watanabe N, Ikenaga H, Shimonaga T, Iwasaki T, et al. Revised index, E/E’, and ischemic stroke in patients with atrial fibrillation and preserved cardiac mass in man. Anatomic validation of the method Circulation. 1977;55(4):613–8.

32. De Luca G, Secco GG, Iorio S, Verdoia M, Bellomo G, Marino P. Short-term effects of aspirin and clopidogrel on mean platelet volume among patients with acute coronary syndromes. A single-center prospective study. Blood Coagul Fibrinolysis. 2012;23(8):756–9.

33. Asher E, Fefer P, Shechter M, Beigel R, Varon D, Shenkman B, et al. Increased mean platelet volume is associated with non-responsiveness to clopidogrel. Thromb Haemost. 2014;112(1):137–41.

34. Yang A, Pizzulli L, Ludzert B. Mean platelet volume as marker of restenosis after percutaneous transluminal coronary angioplasty in patients with stable and unstable angina pectoris. Thromb Res. 2006;117(4):371–7.

35. Arslan OZ, Ozkan B, Kutlu R, Karal H, Sahin DY, Kaypakli O, et al. Relationship between platelet indices and international normalized ratio in patients with non-valvular atrial fibrillation. Platelets. 2014;25(5):311–6.

36. Colkesen Y, Acil T, Abayli B, Yigit F, Katircibasi T, Kocum T, et al. Mean platelet volume is elevated during paroxysmal atrial fibrillation: a marker of increased platelet activation? Blood Coagul Fibrinolysis. 2012;23(5):367–9.

37. Turgut O, Zorlu A, Kilicli F, Cinar Z, Yucel H, Tandogan I, et al. Atrial fibrillation is associated with increased mean platelet volume in patients with type 2 diabetes mellitus. Platelets. 2013;24(6):495–7.

38. Yarıloglu M, Kaya MG, Ardic I, Dogdu O, Kasapkara HA, Guntrak E, et al. Relationship between mean platelet volume levels and subclinical target organ damage in newly diagnosed hypertensive patients. Blood Press. 2011;20(2):92–7.

39. Bulur S, Onder H, Adantas Y, Ekinouz I, Kilic AC, Yalcin S, et al. Relationship between indices of end-organ damage and mean platelet volume in hypertensive patients. Blood Coagul Fibrinolysis. 2012;23(5):367–9.

40. Yavuzkiran MF, Kurtoglu E, Yilmaz M, Korkmaz H, Calmak T, Dogdu O, et al. Relationship between mean platelet volume elevation and left ventricular mass index in hypertensive patients. J Int Med Res. 2014;42(3):781–7.

41. Pusuroglu H, Calmak HA, Erturk M, Akbulut O, Akkaya E, Tosu AR, et al. Assessment of the relation between mean platelet volume, non-dipping blood pressure pattern, and left ventricular mass index in sustained hypertension. Med Sci Monit. 2014;20:2020–6.

42. Yazici HU, Poyraz F, Sen N, Tavil Y, Turfan M, Tulumac M, et al. Relationship between mean platelet volume and left ventricular systolic function in patients with metabolic syndrome and ST-elevation myocardial infarction. Clin Invest Med. 2011;34(6), E360.

43. Kosinuk J, Breitbart O, Bode K, Korone J, Ayra A, Gaspar T, et al. Left ventricular diastolic dysfunction and thromboembolic risk in atrial fibrillation: diastolic dysfunction and thromboembolic risk in AF. Int J Cardiol. 2013;168(1):547–8.

44. Lee SH, Choi S, Chung WJ, Byun YS, Ryu SK, Pyun WB, et al. Tissue Doppler index, E/E, and ischemic stroke in patients with atrial fibrillation and preserved left ventricular ejection fraction. J Neurol Sci. 2008;271(1–2):146–52.

45. Chung I, Choudhury A, Patel J, Lip GY. Soluble CD40L, platelet surface CD40L and total platelet CD40L in congestive heart failure: relationship to platelet volume, mass and granularity. J Intern Med. 2008;263(3):313–21.

46. Vagdatli E, Gounari E, Lazaridou E, Katsibourli E, Tsikopoulou F, Labrianou I. Platelet distribution width: a simple, practical and specific marker of activation of coagulation. Hippokratia. 2010;14(1):28–32.